Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0948265 (metabolic syndrome)
 24,271 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A unified definition of metabolic syndrome, considered a common feature of cardiovascular risk, is lacking. The aim of this study was to compare the prevalence of this syndrome in patients with ischemic heart disease using two diagnostic criteria: the European Group of Resistance to Insulin and the National Cholesterol Education Program. We designed an observational, cross-sectional study of the factors that make up metabolic syndrome in subjects diagnosed with coronary heart disease. A total of 169 patients aged 35 to 79 years were studied (129 men and 40 women). With the European group criterion the percentage of patients with metabolic syndrome was 43.7%, whereas the American group criterion yielded a prevalence of 40.8% (no significant difference). The prevalence of metabolic syndrome among patients with ischemic heart disease is high. The diagnostic criteria used are similar and do not differ significantly, although diagnostic concordance was only 50%.
 ...
PMID:[Metabolic syndrome in patients with coronary heart disease. Results of using different diagnostic criteria]. 1537 96

In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (<100 mg/dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome.
 ...
PMID:Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. 1544 72

During 15 years criteria of metabolic syndrome has undergone definite changes. According to Adult Treatment Panel III of National Cholesterol Education Program metabolic syndrome is diagnosed in the presence of 3 of 5 following signs: waist circumference>/=102 or small i, Ukrainian88 cm in men and women, respectively; triglycerides small i, Ukrainian150 mg/dl, high density lipoprotein cholesterol <39 mg/dl; blood pressure >/=130/85 mm Hg and fasting blood glucose >/=110 mg/dl. Metabolic syndrome is widely spread in populations. Its prevalence ranges from 10.6% in China to 24% in USA and is closely related to life style and age. In a cohort of subjects with history of hypertension at least 5 years and diabetes type2 metabolic syndrome was found in 64 and 88%, respectively. Metabolic syndrome has rather high atherogenic potential and is associated with incidence of ischemic heart disease 2.6-3.0, ischemic heart disease mortality - 2.9-4.2, total mortality - 1.9-2.1 times higher compared with other diseases.
 ...
PMID:[Epidemiological aspects of metabolic syndrome.]. 1547 67

Polyunsaturated fatty acids of n-3 family play an important role in the prevention of ischemic heart disease, as was shown in many epidemiological as well as intervention studies. These fatty acids are essential and human organism is fully dependent on their dietary intake from chloroplast of green plants and fat of aquatic animals. Cardioprotective action of these acids results from their complex effect (antiarrhytmic, antithrombotic, antiinflammatory, hypolipidemic etc.). These acids can, with the exception of glucose homeostasis, favourably influence individual components of the metabolic syndrome. Beneficial effects of n-3 polyunsaturated fatty acids are supposed also in chronic inflammatory and autoimmune diseases, psychiatric-neurological diseases and malignant tumours. In the case of rheumatoid arthritis, antiinflammatory effects of polyunsaturated fatty acids were proven. In general, favourable effects of the optimal income of n-3 polyunsaturated fatty acids can be explained by the influencing of cellular metabolic functions, incorporation into membrane phospholipids, modulation of enzymes and signal molecules as well as by direct impact on gene expression. Polyunsaturated fatty acids of n-3 family have high therapeutic potential, which results from the combined action on different levels of cell functions. In some diseases, their effect is nearly pharmacological - prevention of the sudden death and fatal myocardial infarction, treatment of hyper- and dyslipoproteinemias, suppression of the inflammatory activity in rheumatoid arthritis. In another group of diseases, they have supporting effect (prevention of the arterial hypertension in metabolic syndrome) and, finally, in the last one (psychiatric-neurological diseases and tumours), more data of defined clinical groups are necessary for final evaluation.
 ...
PMID:[Pathophysiology of and clinical significance of polyunsaturated fatty acids n-3 family]. 1598 80

A novel cardiac syndrome of left ventricular apical ballooning (Takotsubo cardiomyopathy-ampulla cardiomyopathy) involves reversible left ventricular apical ballooning (during systole) of acute onset with chest pain, electrocardiographic changes, and minimal elevation of cardiac enzymes resembling acute myocardial infarction, but without evidence of myocardial ischemia or injury. Patients have no angiographic evidence of coronary artery stenosis and there is almost always a complete recovery of left ventricular function in days to weeks. The precise etiologic basic of this syndrome is not clear but most likely it is a non-ischemic, metabolic syndrome caused by stress-induced activation of the cardiac adrenoceptors in absence of ischemia and reperfusion. Reported here is a case of stress-induced transient left ventricular apical ballooning syndrome in a young woman.
 ...
PMID:Transient left ventricular apical ballooning: a novel heart syndrome. 1598 10

178 patients with metabolic syndrome, 92 patients with II stage hypertonic disease and 47 patients with chronic Ischemic heart disease have been observed. Intracardiac hemodynamics has been estimated using ultrasound apparatus LOGIC-500 "General Electric". The obtained data confirmed structural-geometrical and functional state of left ventricle in patients with metabolic syndrome to have some peculiarities which can not be explained only by intracardiac hemodynamics of patients with hypertonic and ischemic heart disease. Special mechanisms of regulation of left ventricle and formation of its functional disorders have been shown to exist in patients with metabolic syndrome.
 ...
PMID:[Structural-geometrical and functional state of the heart left ventricle in patients with metabolic syndrome]. 1602 74

On the basis of traditional risk factors, a large number of individuals in the United States can be classified as at intermediate risk for the development of ischemic heart disease. The diagnosis of the metabolic syndrome can help determine whether patients at intermediate risk should be considered for more aggressive risk-factor reduction. The measurement of novel risk factors, such as inflammatory markers, can identify a group of patients at high intermediate risk. The Adult Treatment Panel of the National Cholesterol Education Program suggests considering a more aggressive low-density lipoprotein cholesterol treatment goal in this group of individuals. In addition, the presence of the metabolic syndrome is highly predictive of the development of diabetes mellitus. A treatment strategy focusing on aerobic exercise and weight loss can help delay or prevent the development of diabetes and can help reduce cardiovascular risk. For significant risk reduction to be achieved, treatment strategies must focus on therapy for all risk factors, including dyslipidemia, hypertension, and insulin resistance.
 ...
PMID:Implications of the metabolic syndrome: the new epidemic. 1609 35

The association between the metabolic syndrome (MS) to ischemic heart disease (IHD) has not been established prospectively in Asian populations. We carried out registry linkage, using unique national identity numbers, to identify incident IHD events in subjects without diabetes mellitus or IHD from two cross-sectional studies of Chinese, Malays and Asian Indians living in Singapore. The risk of IHD associated with the MS (NCEP ATP III criteria) was determined by Cox-proportional hazards regression before and after adjustment for age, sex, ethnic group and current cigarette smoking. We also assessed the utility of modified Asian criteria (reducing the waist circumference (WC) used to define central obesity to 90 cm in men and 80 cm in women) on the risk of IHD associated with the MS. This study provided 38,157.4 person-years in 4042 subjects who experienced 93 incident IHD events. MS (as defined by the NCEP ATP III criteria) was associated with increased risk of IHD (HR3.09; 95% CI 1.96-4.88). Those who satisfied only the modified Asian criteria, but not the NCEP ATP III criteria, were also at increased risk of IHD (HR 2.13; 95% CI 0.99-4.58). It would be appropriate to lower the cut-off for WC used for the diagnosis of the MS in such populations.
 ...
PMID:Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. 1611 23

The relation between erectile dysfunction (ED) and cardiovascular disease (CVD) is relevant and important to all fields of medicine. ED is often not considered in the same context as traditional cardiovascular conditions, such as hypertension, dyslipidemia, ischemic heart disease, diabetes mellitus, or the insulin resistance/metabolic syndrome complex. Specific guidelines for treating men with ED and known CVD have been established and recently updated. This article focuses on ED as an early symptom of systemic CVD as well as insulin resistance and the metabolic syndrome. The diagnosis of ED and the subsequent evaluation of underlying cardiovascular risk factors could become a powerful clinical tool to help with early detection of atherosclerotic disease and enhance overall preventive vascular health in men.
 ...
PMID:Sexual dysfunction and cardiovascular disease: integrative concepts and strategies. 1638 69

We sought to examine the relative contribution to cardiovascular risk of the metabolic syndrome (MS) compared with that of a high LDL cholesterol level in a population-based study of 2493 men and women, age 41-72 years, without major cardiovascular diseases at baseline. MS was defined according to the National Cholesterol Education Program criteria. The study population was subdivided into four groups on the basis of presence (prevalence: 15%) or absence of MS (85%) and presence (15%) or absence of high LDL cholesterol (85%) defined as a level >5.02 mmol/L or </=5.02 mmol/L. After 9.5 years, 233 had a cardiovascular endpoint (cardiovascular death, ischemic heart disease, and stroke). In proportional-hazard models, adjusting for age, sex, and smoking, and with subjects without MS and LDL cholesterol </=5.02 mmol/L as reference (73%), the relative risk of an endpoint (95% CI) was 1.49 (1.04-2.13) in participants without MS and LDL cholesterol >5.02 mmol/L (12%), 1.80 (1.26-2.57) in subjects with MS and LDL cholesterol </=5.02 mmol/L (12%) and 3.21 (1.99-5.17) in participants with both MS and LDL cholesterol >5.02 mmol/L (3%). In a general population, MS was associated with a cardiovascular risk comparable with that of a high LDL cholesterol level.
 ...
PMID:Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. 1643 Sep 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>